Oncology/Haematology pipeline

INN / Compound	Class	Condition or disease	Discovery	Preclinical	Phase I	Phase II	Phase III	In Registration	Approved*
Vinorelbine	Chemo-therapy	Non small cell lung cancer							
		Advanced breast cancer							

INN / Compound	Class	Condition or disease	Discovery	Preclinical	Phase I	Phase II	Phase III	In Registration	EMA Approved
Vinflunine	Chemo-therapy	Advanced or metastatic transitional-cell carcinoma of the urothelial tract							

* Vinorelbine was approved by National Health Authorities (before EU centralized procedure implementation)

This display includes ongoing clinical trials for both approved and investigational compounds.
Inclusion in this display does not imply regulatory approval for these compounds or all indications.
Approved products should be used in accordance with their prescribing information. Information about the trials can be found at www.ClinicalTrials.gov

HQ--06-22-2200019 V 2.0 – Preparation date: April 2023

Oncology/Haematology pipeline



† Encorafenib + cetuximab is approved for *BRAFV600E* mutant mCRC, after prior systemic therapy; encorafenib + binimetinib is approved for unresectable or metastatic *BRAF*-mutant melanoma.
* Clinical development under Pfizer sponsorship.
1. In licensing with *Array (Pfizer inc. Group),* Boulder, USA; 2. In licensing with PUMA Biotechnology inc., Los Angeles, USA; 3. In licensing with ATARA Biotherapeutics inc., South San Francisco, USA.

This display includes ongoing clinical trials for both approved and investigational compounds. Inclusion in this display does not imply regulatory approval for these compounds or all indications.
Approved products should be used in accordance with their prescribing information. Information about the trials can be found at www.ClinicalTrials.gov
Efficacy and safety of encorafenib, binimetinib and neratinib have not been established for investigational uses.

HQ--06-22-2200019 V 2.0 – Preparation date: April 2023

Oncology/Haematology pipeline

INN / Compound	Class	Condition or disease	Discovery	Preclinical	Phase I	Phase II	Phase III	In Registration	EMA Approved
K01401	Monoclonal antibody anti-VISTA*	Solid tumors							
STX-241[4]	Targeted therapy	Solid tumors with *EGFR* exon 19/C797S or exon 21/C797S double mutations							
STX-721[4]	Targeted therapy	Solid tumors with *EGFR* exon 20 insertion mutation							



* VISTA, V-domain Ig suppressor of T-cell Activation.

4. In co-development partnership with Scorpion Therapeurics Inc., Boston, USA.
The sponsor of these studies could be Pierre Fabre Medicament or Scorpion Therapeutics Inc.

This display includes ongoing clinical trials for both approved and investigational compounds.
Inclusion in this display does not imply regulatory approval for these compounds or all indications.
Approved products should be used in accordance with their prescribing information. Information about the trials can be found at www.ClinicalTrials.gov

HQ--06-22-2200019 V 2.0 – Preparation date: April 2023